Novartis' oral multiple sclerosis drug meets main goal in late stage studies
- Posted on September 1, 2026
- By Bing News
- 0 Views
- 1 min read
In brief
Generating AI summary…
Novartis' oral multiple sclerosis drug meets main goal in late stage studies
LONDON, Sept 1 (Reuters) - Swiss drugmaker Novartis said on Tuesday that its oral drug, remibrutinib, met the main goals in two late-stage studies, showing superiority over a rival drug in reducing relapse rates in patients with a form of multiple sclerosis. Investors have been on the lookout for data from three experimental drugs - pelacarsen, multiple sclerosis drug remibrutinib and genetic
